INVICTUS trial

INVICTUS was a Phase 3 trial that allowed for US approval in May of 2020 for the use of Qinlock (Ripretinib) in the 4L setting.

The trial results can be seen in a paper written by Dr Zalcberg et al. here

Marina Symcock (co-Chair of GSI) and Neeta Somaiah M.D., (Associate Professor, Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX) have written a plain language summary of the INVICTUS trial published in Future Oncology Online on Oct. 18 2021 here .

You can download a pdf from here: INVICTUS trial summary

INTRIGUE trial

Deciphera has announced the top-line results of the INTRIGUE trial examining the use of QINLOCK (Ripretinib) in the 2L setting. Please find a link to the press release here for your review.

The results of INTRIGUE have been highly anticipated and while the outcomes are not as Deciphera had hoped, they state that their commitment to the GIST patient community continues to be a priority.